Clinical trials: Atherosclerotic Ischemic Disease
Coronary Artery Disease
A Clinical Trial to Assess the SYNERGY 48 mm Stent System for the Treatment of Atherosclerotic Lesion(s)
EVOLVE 48 is a prospective, open label, single arm, multi-center trial. The purpose of this study is to assess the FDA requirement for safety and effectiveness of the SYNERGY 48 mm Coronary Stent System for the treatment of…
- Trial name
- EVOLVE48 (NCT03350542)
- Testing
- SYNERGY 48 mm
- Where
- 15 sites in United States, Latvia and 2 more
- Volunteers
- 100 people
- Sponsor
- Boston Scientific Corporation
Cardiovascular Diseases, Myocardial Infarction
Subclinical Cardiovascular Disease in Psoriatic Disease
This study will look at how chronic inflammation seen in psoriatic disease translates into the increased atherosclerotic and thrombotic risk and how treatment reduces this CVD risk.
- Conditions
- Cardiovascular Diseases, Myocardial Infarction, Atherosclerotic Cardiovascular Disease, Thrombotic Vascular Disease
- Trial name
- NCT03228017
- Testing
- Aspirin and/or Atorvastatin
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))
The REVEALPLAQUE Study: A pRospEctiVe, multicEnter Study to AnaLyze PLAQUE Using CCTA
This study will evaluate the level of agreement between noninvasive CCTA (coronary computed tomography angiography)-based quantification and characterization of coronary atherosclerosis and invasive IVUS (intravascular…
- Trial name
- REVEALPLAQUE (NCT05138289)
- Testing
- Total Plaque Volume
- Where
- United States
- Volunteers
- 258 people
- Sponsor
- HeartFlow, Inc.
Coronary Artery Disease, Carotid Artery Diseases
Evaluate Carotid Artery Plaque Composition by Magnetic Resonance Imaging in People Receiving Cholesterol Medication
Atherosclerosis is a condition that occurs when fatty deposits build up along the inner walls of arteries. This study will examine the effectiveness of a combination of cholesterol-lowering medications at decreasing the fat…
- Conditions
- Coronary Artery Disease, Carotid Artery Diseases, Atherosclerosis
- Trial name
- CPC (NCT00715273)
- Testing
- Atorvastatin, Niacin, Colesevelam
- Where
- 4 sites in United States
- Volunteers
- 217 people
- Sponsor
- University of Washington
Coronary Artery Disease
The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions
The purpose of this study is to evaluate the safety and effectiveness of the PROMUS Element™ Everolimus-Eluting Coronary Stent System for the treatment of patients with up to 2 de novo atherosclerotic coronary artery lesions.
- Trial name
- PLATINUM (NCT00823212)
- Testing
- PROMUS Coronary Stent System, PROMUS Element Coronary Stent System, Aspirin
- Where
- 133 sites in United States, Australia and 15 more
- Volunteers
- 1,530 people
- Sponsor
- Boston Scientific Corporation
Carotid Artery Stenosis, Cerebral Infarction
Bacteria in Atherosclerotic Plaques and Adverse Events
This study is a prospective, multicenter cohort study conducted in western China. The registry study is primarily conducted at the Department of Neurosurgery, Tangdu Hospital, with participation from the Departments of…
- Conditions
- Carotid Artery Stenosis, Cerebral Infarction, Diabetes, Bacteria
- Trial name
- NCT06935279
- Testing
- Carotid Endarterectomy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Tang-Du Hospital
Coronary Artery Disease
Clinical Impact of Cardiac Photon-Counting Detector CT
The purpose of this research trial is to determine whether images taken using a Photon Counting Detector CT scanner (PCD-CT) provide clinically important information about the severity of suspected coronary artery disease and…
- Trial name
- NCT05240807
- Testing
- Photon-counting detector computed tomography (PCD-CT)
- Where
- United States
- Volunteers
- 276 people
- Sponsor
- Mayo Clinic
Coronary Artery Disease, Type 2 Diabetes Mellitus
Direct Renin Inhibition Effects on Atherosclerotic Biomarkers
The investigators aim to assess if a new blood pressure medication, aliskiren, reduces various biomarkers of heart disease found in the blood in patients with a history of both heart disease and type 2 diabetes.
- Trial name
- NCT00818779
- Testing
- Aliskiren, Amlodipine
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Texas Tech University Health Sciences Center
Coronary Artery Disease
PLATINUM Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions-Pharmacokinetics (PLATINUM PK)
The purpose of this study is to evaluate the safety and effectiveness of the PROMUS Element™ Everolimus-Eluting Coronary Stent System for the treatment of patients with up to 2 de novo atherosclerotic coronary artery lesions.
- Trial name
- PLATINUM PK (NCT01510327)
- Testing
- PROMUS Element Everolimus-Eluting Coronary Stent System, Aspirin, Thienopyridine
- Where
- 5 sites in United States, Japan
- Volunteers
- 22 people
- Sponsor
- Boston Scientific Corporation
Stable Angina, Heart Failure
Plasmonic Nanophotothermal Therapy of Atherosclerosis
The investigators hypothesize that the nanoburning is a very challenging technique to demolish and reverse the plaque especially in combination with stem cell technologies promising the functional restoration of the vessel wall.
- Conditions
- Stable Angina, Heart Failure, Atherosclerosis, Multivessel Coronary Artery Disease
- Trial name
- NANOM-FIM (NCT01270139)
- Testing
- Transplantation of nanoparticles, Transplantation of iron-bearing nanoparticles, Stenting
- Where
- 4 sites in Netherlands, Russia
- Volunteers
- 180 people
- Sponsor
- Ural State Medical University
Aortic Stenosis, Brain Infarction
Neuroprotection in Patients Undergoing Aortic Valve Replacement
To evaluate the efficacy and safety of embolic protection devices to reduce ischemic brain injury in patients undergoing surgical aortic valve replacement (AVR).
- Conditions
- Aortic Stenosis, Brain Infarction, Cerebrovascular Accident, Stroke
- Trial name
- NCT02389894
- Testing
- Embol-X Embolic Protection Device, CardioGard Cannula
- Where
- 18 sites in United States, Canada
- Volunteers
- 383 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Intracranial Atherosclerosis
Post Market Surveillance Study of the Wingspan Stent System
The primary objective of this study is to evaluate the rate of stroke and/or death in patients treated with the Wingspan Stent System, according to the Indications for Use, within 72 hours post procedure.
- Trial name
- WEAVE (NCT02034058)
- Testing
- Wingspan Stent System
- Where
- 26 sites in United States
- Volunteers
- 152 people
- Sponsor
- Stryker Neurovascular
Atherosclerosis
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or stroke) in people with coronary heart disease.
- Trial name
- STABILITY (NCT00799903)
- Testing
- Darapladib
- Where
- 650 sites in United States, Argentina and 37 more
- Volunteers
- 15,828 people
- Sponsor
- GlaxoSmithKline
Coronary Artery Disease
NIRS Ticagrelor Evaluation
The Impact of Ticagrelor on Coronary Atherosclerotic Lipid Pool and Inflammation Assessed by Near-Infrared Spectroscopy study will evaluate whether ticagrelor leads to a 20% reduction in the LCBI with NIRS/IVUS suggesting…
- Trial name
- NCT02282332
- Testing
- Ticagrelor
- Volunteers
- 30 people
- Sponsor
- Medstar Health Research Institute
Renal Artery Obstruction, Hypertension, Renovascular
Effects of Intravenous Bendavia™ on Reperfusion Injury in Patients Undergoing Angioplasty of the Renal Artery
This was a Phase 2a prospective, single center, randomized, double-blind, placebo-controlled study designed to assess the efficacy, pharmacokinetics, safety and tolerability of IV elamipretide for reduction of reperfusion injury…
- Conditions
- Renal Artery Obstruction, Hypertension, Renovascular, Ischemia Reperfusion Injury
- Trial name
- EVOLVE (NCT01755858)
- Testing
- Bendavia
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Stealth BioTherapeutics Inc.
Coronary Artery Disease
The EVOLVE China Clinical Trial
The purpose of this study is to assess the safety and effectiveness of the SYNERGY™ Coronary Stent System for the treatment of subjects with atherosclerotic lesion(s) ≤ 34 mm in length (by visual estimate) in native coronary…
- Trial name
- EVOLVE-CHINA (NCT01966159)
- Testing
- SYNERGY Investigational Device, PE Plus Investigational Device
- Where
- 14 sites in China
- Volunteers
- 412 people
- Sponsor
- Boston Scientific Corporation
Atherosclerosis
PE PREMIER CHINA CLINICAL TRIAL
PE PREMIER China: A Prospective, Multicenter Trial to Assess the Promus PREMIERTM Everolimus-Eluting Platinum Chromium Coronary Stent System for the Treatment of Atherosclerotic Lesion(s)
- Trial name
- NCT02230254
- Testing
- Percutaneous coronary intervention PROMUS PREMIER
- Volunteers
- 101 people
- Sponsor
- Boston Scientific Corporation
Atherosclerosis, Coronary Artery Disease
NG PROMUS Stent System for the Treatment of Atherosclerotic Coronary Lesions
NG PROMUS: A Prospective, Multicenter Trial to Assess the NG PROMUS Everolimus-Eluting Platinum Chromium Coronary Stent System (NG PROMUS Stent System) for the Treatment of Atherosclerotic Lesion(s)
- Trial name
- NCT01703000
- Testing
- Percutaneous coronary intervention (NG PROMUS)
- Where
- 9 sites in Australia, New Zealand and 1 more
- Volunteers
- 100 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease
The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s)
The purpose of this study is to assess the safety and effectiveness of the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System for the treatment of subjects with atherosclerotic lesion(s) ≤ 34 mm in length (by…
- Trial name
- NCT01665053
- Testing
- PROMUS Element Plus, SYNERGY
- Where
- 126 sites in United States, Australia and 14 more
- Volunteers
- 1,684 people
- Sponsor
- Boston Scientific Corporation
Coronary Heart Disease
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
This study will assess the effect of RO4607381, compared to placebo, on atherosclerotic plaque in patients with coronary heart disease (CHD) including patients with other CHD risk factors.
- Trial name
- NCT00655473
- Testing
- Dalcetrapib (RO4607381)
- Where
- 12 sites in United States, Canada
- Volunteers
- 130 people
- Sponsor
- Hoffmann-La Roche